Fledg­ling biotech Syn­tim­mune looks to take flight in the clin­ic with a new CEO and a slight­ly less vir­tu­al busi­ness mod­el

Syn­tim­mune is still a large­ly un­teth­ered, vir­tu­al biotech with a tiny crew of staffers backed by a pla­toon of con­sul­tants. But to­day it’s just a lit­tle less vir­tu­al and a lit­tle more fo­cused on build­ing a com­pa­ny.

David de Graaf, an ex­pe­ri­enced R&D vet, is leav­ing his role as a ven­ture part­ner at Ap­ple Tree and tak­ing the helm at the biotech, which is con­cen­trat­ing on ramp­ing up a slate of Phase Ib/IIa stud­ies for a pipeline of drugs tar­get­ing IgG-me­di­at­ed au­toim­mune dis­eases by block­ing FcRn-IgG in­ter­ac­tions. Burt Adel­man, for­mer R&D chief at Dyax, is join­ing the board. And the team will have an ex­tra $8 mil­lion in fresh fund­ing to get the clin­i­cal game un­der­way in earnest.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER